Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Omicron has caused the U.S. to install travel bans against several South African countries while vaccine makers rush to test their vaccines against it. For that news and more, continue reading.
The deal adds LNG-451, a highly selective brain-penetrant precision therapy targeting EGFR exon 20 insertion mutations, to its pipeline.
New York-based Turnstone Biologics announced it is partnering with the Moffitt Cancer Center to develop tumor-infiltrating lymphocyte (TIL) therapies.
Quell Therapeutics scooped up $156 million in a Series B round this week. The company utilizes regulatory T cells to treat a variety of autoimmune and inflammatory diseases.
Results from its GEM-3 trial on VYJUVEK demonstrated statistical significance in its ability to promote complete wound healing within six months compared to a placebo.
In October, Vertex Pharmaceuticals announced stunning results in a type 1 diabetes patient who had been dosed with the company’s experimental therapy.
As the late-stage trials continue to progress, Talaris is rapidly ramping up its resources and investments.
The latest data from Merck and Ridgeback Biotherapeutics’ MOVe-OUT trial on the use of molnupiravir to treat COVID-19 in adults has shown a lower efficacy than previously reported.
The World Health Organization officially declared omicron – aka. B.1.1.529 – a variant of concern (VOC) on Friday.
Treatment for non-alcoholic steatohepatitis (NASH), a severe form of fatty liver disease, consists mainly of lifestyle modification – specifically dieting and weight loss.
Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look.
The U.S. Food and Drug Administration has a very busy calendar for the end of November and beginning of December. Here’s a look.